WhatsApp
backNews Article

Bhageria Industries obtains EDQM GMP approval for Dexamethasone production at Vapi plant

European Directorate for the Quality of Medicines & Healthcare attests compliance with EU GMP standards under CEP No. 2024-138 following February 2026 inspection

Bhageria Industries Limited received the Good Manufacturing Practice (GMP) attestation from the European Directorate for the Quality of Medicines & Healthcare (EDQM) for its Vapi facility, confirming compliance with EU GMP standards for manufacturing Dexamethasone under CEP No. 2024-138.

1 day ago|BHAGERIA+0.00%
Bhageria Industries Limited530803Legal / Regulatory

Bhageria Industries Limited

Legal / Regulatory

Bhageria Industries Limited announced receipt of the Good Manufacturing Practice (GMP) attestation from the European Directorate for the Quality of Medicines & Healthcare (EDQM) for its manufacturing site in Vapi, Gujarat, related to Dexamethasone production under Certificate of Suitability (CEP) No. 2024-138.

The EDQM conducted a GMP inspection at Bhageria's Vapi facility from February 4 to February 6, 2026. This attestation confirms the company's adherence to the European Union Good Manufacturing Practice requirements as part of the CEP certification framework for Dexamethasone manufacture.

The manufacturing facility is located at Plot No 6102/10, GIDC IV Phase, Vapi, Gujarat 396195, India.

This approval is significant for Bhageria Industries as it ensures compliance with stringent European standards, enabling continued or expanded supply of Dexamethasone in regulated markets.

Highlights

  • Received EDQM Good Manufacturing Practice (GMP) attestation under Reference Number INSP 2025-052-PO1.
  • Inspection conducted from February 4 to February 6, 2026, at the Vapi manufacturing site.
  • Approval pertains specifically to Dexamethasone produced under Certificate of Suitability (CEP) No. 2024-138.
  • Confirms compliance with European GMP standards relevant to medicine quality and healthcare requirements.

Key Data Snapshot

Inspection reference numberINSP 2025-052-PO1
Inspection datesFebruary 4-6, 2026
Product coveredDexamethasone
Certificate of Suitability (CEP) number2024-138
Manufacturing facility locationPlot No 6102/10 GIDC IV Phase, Vapi, Gujarat 396195, India
Date of announcementNovember 14, 2026

What happened

  • Bhageria Industries Limited received the Good Manufacturing Practice (GMP) attestation from the European Directorate for the Quality of Medicines & Healthcare (EDQM).
  • The attestation confirms compliance with applicable European GMP regulations under the Certificate of Suitability framework.
  • The approval pertains to the company's manufacturing of Dexamethasone at its Vapi facility in Gujarat.

Key details

  • The EDQM inspection was held from February 4 to February 6, 2026, at Bhageria’s Vapi manufacturing site.
  • The inspection reference number is INSP 2025-052-PO1.
  • Compliance is specifically related to Dexamethasone produced under Certificate of Suitability number 2024-138.

Regulatory and governance context

  • The attestation demonstrates conformity with European Union Good Manufacturing Practice standards, essential for maintaining supply authorization in European and other regulated markets.
  • The Certificate of Suitability (CEP) confirms that the active pharmaceutical ingredient meets the quality standards required by the European Pharmacopoeia.

More News on Legal / Regulatory

View all

Latest corporate announcements and market updates in Legal / Regulatory.

View all news
Bhageria Industries obtains EDQM GMP approval for | Stockk News